Acceleron Pharma, Inc.;Ludwig Institute for Cancer Research, Ltd.
发明人:
申请号：
EP18154273.9
公开号：
EP3398966A1
申请日:
2009.05.01
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction
